植物分子用于治疗帕金森病
Krishn Kumar Agrawal1,2, Chandra Veer2, Yogesh Murti2
1Dr. A.P.J. Abdul Kalam Technical University, Lucknow-226031, India.
Central nervous system agents in medicinal chemistry
|December 19, 2024
概括
帕金森病涉及神经元损失和运动缺陷. 植物分子通过减少氧化应激和亡来提供神经保护,为新的帕金森病疗法铺平了道路.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 影响了65岁以上的1%的人,其特点是尼格罗斯特里亚特途径中多巴胺能神经元的损失.
- 帕金和PINK1基因的突变损害了线粒体和线粒体功能,导致PD的发病.
- 病发症与运动障碍 (勃拉迪基尼西亚,刚性,震) 和非运动症状有关,受α-synuclein聚合和蛋白质分解防御障碍的影响.
研究的目的:
- 为了研究帕金森病背后的机制.
- 探索植物分子在帕金森病中的神经保护潜力.
- 为了确定帕金森病的新型治疗策略.
主要方法:
- 关于帕金森病机制的现有文献的审查,包括遗传因素,氧化应激,铁亡,线粒体衰竭和神经炎症.
- 对涉及PD的信号通路的分析,例如α-synuclein聚合.
- 检查特定植物分子 (黄素,β-阿米林,柏柏林,素,甘酸) 的神经保护作用.
主要成果:
- 帕金森病的发病过程涉及复杂的相互作用,包括氧化应激,铁,线粒体功能障碍和神经炎症.
- 植物分子通过降低活性氧物种 (ROS) 水平来显示神经保护性质.
- 这些化合物减轻α-synuclein的毒性,并保护细胞免受亡,表明治疗潜力.
结论:
- 了解帕金森病的复杂机制对于开发有效的治疗方法至关重要.
- 植物分子是帕金森病治疗的有希望的途径,因为它们具有多方面的神经保护作用.
- 对这些机制和植物分子的进一步研究可以导致对PD进行改进的治疗干预措施的开发.
相关概念视频
01:24Parkinson's Disease: Treatment
216
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
216
01:15Parkinson's Disease: Overview
476
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
476
01:37Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
01:29Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
01:21EPS and iPS Cells in Disease Research
2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
01:22Alzheimer's Disease: Treatment
162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162